Reply: Comment on alemtuzumab and inclusion body myositis

Sir, Dr Greenberg misinterprets several important aspects of our study, including the scope and applied methodology. Below we have addressed the points raised in his correspondence. This was a proof-of principle molecular clinicopathological study designed to investigate the effect of alemtuzumab on endomysial T cells and disease progression; it was not primarily a trial of clinical efficacy. A...

متن کامل

Comment on alemtuzumab and inclusion body myositis.

Sir, The recent Brain publication (Dalakas et al., 2009) describing a clinical study of alemtuzumab in patients with inclusion body myositis nicely demonstrates the feasibility of enrolling and following a cohort of these patients over a long period of time as participants in an intervention study. The authors state that ‘in [inclusion body myositis] one series of alemtuzumab infusions can slow...

متن کامل

LETTER TO THE EDITOR Reply to: Comment on alemtuzumab and inclusion body myositis

Sir, Dr Greenberg misinterprets several important aspects of our study, including the scope and applied methodology. Below we have addressed the points raised in his correspondence. This was a proof-of principle molecular clinicopathological study designed to investigate the effect of alemtuzumab on endomysial T cells and disease progression; it was not primarily a trial of clinical efficacy. A...

متن کامل

LETTER TO THE EDITOR Reply: Comment on alemtuzumab and inclusion body myositis

Sir, Dr Greenberg misinterprets several important aspects of our study, including the scope and applied methodology. Below we have addressed the points raised in his correspondence. This was a proof-of principle molecular clinicopathological study designed to investigate the effect of alemtuzumab on endomysial T cells and disease progression; it was not primarily a trial of clinical efficacy. A...

متن کامل

LETTER TO THE EDITOR Comment on alemtuzumab and inclusion body myositis

Sir, The recent Brain publication (Dalakas et al., 2009) describing a clinical study of alemtuzumab in patients with inclusion body myositis nicely demonstrates the feasibility of enrolling and following a cohort of these patients over a long period of time as participants in an intervention study. The authors state that ‘in [inclusion body myositis] one series of alemtuzumab infusions can slow...

متن کامل

Reply: Comment on alemtuzumab and inclusion body myositis

نویسندگان

چکیده

منابع مشابه